PARIS, France, March 11, 2024, 04:30 pm CET – Pharnext SA ( FR001400N1P4 - ALPHA) (the “Company”), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, provides a comprehensive overview of operational, strategic and financial issues following recent announcements.